<DOC>
	<DOCNO>NCT01210170</DOCNO>
	<brief_summary>Glucocorticosteroids inhibit disposal organic cation block organic cation transporter express non-neuronal cell , thereby interfere inactivation organic cation intracellular enzyme . Beta2-adrenergic agonist organic cation , concentration inhale beta2-adrenergic agonist beta2-adrenergic receptor sit smooth muscle likely increase inhaled glucocorticosteroids ( ICS ) ICS ' effect glucocorticosteroid-sensitive organic cation transporter . The investigator show human airway vascular smooth muscle cell glucocorticosteroid action organic cation uptake occur within minute , involve gene transcription protein synthesis , mediate classical steroid receptor , cell membrane-linked . In present proposal , investigator wish use different single dos mometasone , clinically effective ICS , administer different time albuterol inhalation subject moderate persistent asthma obstruct time study . With approach investigator test hypothesis single inhalation mometasone cause acute , transient , dose-dependent potentiation beta2-adrenergic bronchodilation . If hypothesis single dose mometasone acutely potentiate beta2-adrenergic bronchodilation correct , result would significant impact treatment strategy involve ICSs beta2-adrenergic agonist patient asthma .</brief_summary>
	<brief_title>Acute Effect Mometasone Beta-adrenergic Airway Airway Vascular Relaxation Severe Asthma</brief_title>
	<detailed_description>Fifteen non-smokers ( male females age 18 65 year ) physician-diagnosed moderate persistent asthma recruit study . The subject allow use inhale controller ( include ICS ) rescue medication . At study entry , asthmatic subject must clinically stable , force pre-bronchodilator one-second expired volume ( FEV1 ) &lt; 75 % predict . Approval protocol request University Miami Institutional Review Board . All subject provide write informed consent . Exclusion criterion : - Cardiovascular disease use cardiovascular medication - Pregnancy - Use oral controller medication asthma ( methylxanthines , systemic glucocorticosteroids , leukotriene modifier ) - An acute respiratory infection within 4 week enrollment . Each subject make 8 visit research laboratory . Procedures : Visit 1 ( screen visit ) : On visit , sign consent form , subject perform spirometry 15 min inhale 180 µg albuterol HFA-MDI use spacer . Visit 2-8 : Subjects qualify study ask return 7 visit follow treatment protocol : - Inhalation 400 µg mometasone 30 min inhalation 180 µg albuterol - Inhalation mometasone placebo 30 min inhalation 180 µg albuterol - Simultaneous inhalation 400 µg mometasone 180 µg albuterol - Simultaneous inhalation mometasone placebo 180 µg albuterol Systemic blood pressure , pulse , O2 saturation , spirometry airway blood flow ( Qaw ) measure mometasone placebo inhalation , 15 min albuterol inhalation except day mometasone albuterol co-administered ; day measurement make 15 min mometasone/albuterol co-administration .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<mesh_term>Adrenergic Agents</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Fifteen nonsmoker ( male females age 18 65 year ) physiciandiagnosed moderate persistent asthma FEV1 &lt; 75 % predict . Cardiovascular disease use cardiovascular medication , pregnancy , use oral controller medication asthma ( methylxanthines , systemic glucocorticosteroids , leukotriene modifier ) , acute respiratory infection within 4 week enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>asthma ,</keyword>
	<keyword>inhaled corticosteroid ,</keyword>
	<keyword>airway blood flow ,</keyword>
	<keyword>mometasone ,</keyword>
	<keyword>albuterol</keyword>
	<keyword>spirometry</keyword>
</DOC>